Denise Braendgaard: We are Now the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation
Denise Braendgaard, General Manager of Novo Nordisk Haemophilia Foundation, shared a post by Novo Nordisk Haemophilia & Haemoglobinopathies Foundation on LinkedIn:
”The day has finally arrived and I can’t hide my excitement: we are waking up to new horizons.
After years of preparation by our Council and Team – and inspired by our incredible partners – we are immensely proud to announce that we are now the Novo Nordisk Haemophilia & Haemoglobinopathies Foundation.
It is much more than adding one word.
It represents hope for people affected by haemoglobinopathies – specifically sickle cell disease and thalassaemia – in low and middle income countries who will benefit from our programmes. At the same time, it reaffirms our unwavering commitment to haemophilia.
It is an expansion of our vision and scope, a bold declaration of our continued, long-term dedication after 20 years of Impacting Care. Together.”
Quoting Novo Nordisk Haemophilia & Haemoglobinopathies Foundation’s post:
”We are now the Novo Nordisk Haemophilia & Haemoglobinopathies Foundation
Proudly, we are unveiling our Foundation’s new chapter:
We are expanding our support beyond people with haemophilia to people with sickle cell disease and thalassaemia as well.
Building on two decades of work in haemophilia, and enabled by a renewed partnership with the Novo Nordisk Foundation and the continued funding from our founder, Novo Nordisk, we are expanding our scope to include haemoglobinopathies. We will apply our proven, partnership-led model to develop tailored programmes that benefit people with haemophilia and haemoglobinopathies, their healthcare professionals, and families – always adapted to local needs.
Let us tell you more here.”
Keep up with Hemostasis Today.
-
Jul 26, 2026, 08:39Roshni Kulkarni: The Human Face of Postpartum Hemorrhage
-
Jul 26, 2026, 08:14Atahar imam Hasan: Universal Artificial Blood and the Future of Trauma Care
-
Jul 26, 2026, 07:40Maha Othman: Leading Scientific Collaboration Across Hemostasis at ISTH 2026
-
Jul 26, 2026, 07:20Pablo Corral: Why Should Dyslipidemia Be Any Different?
-
Jul 26, 2026, 06:46Marios Georgakis: Largest GWAS of Transient Ischemic Attacks Reveals New Genetic Insights into Stroke Risk
-
Jul 26, 2026, 06:40Aaron Iding: From Virtual Meetings to Meaningful Connections at ISTH 2026
-
Jul 26, 2026, 06:36How Stroke Services Have Evolved Over the Past 8 Years in Kazakhstan – International Journal of Stroke
-
Jul 26, 2026, 06:31Leonardo Roever: Non-LDL Biomarkers and The Potential Future Applications for 2ry Stroke Prevention
-
Jul 26, 2026, 06:27Chiara Terzo: New Insights into Haemodialysis in Haemophilia B